Stockreport

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

Dare Bioscience, Inc.  (DARE) 
Last dare bioscience, inc. earnings: 8/14 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.darebioscience.com/investor-relations
PDF $22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make up [Read more]